Skip to content

Serotonin research published in 2024

Page 5 of 6: studies 81 to 100 of 105, newest first. Back to the serotonin overview

Studies

Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain.

AJNR. American journal of neuroradiology February 15, 2024 Paloma C Frautschi, Ajay P Singh, Nicholas A Stowe et al. 5 citations

The neurobiological mechanisms underpinning psychiatric disorders such as treatment-resistant major depression, post-traumatic stress disorder, and substance use disorders, remain unknown. Psychedelic compounds, such as psilocybin, lysergic acid diethylamide, and N,N-dimethyltryptamine, have emerged as potential therapies for these disorders because of their hypothesized ability to induce...

DOI: 10.3174/ajnr.a8118 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Brain research Therapeutic medicine

Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging February 9, 2024 Yasmin Schmid, Anya K. Bershad 15 citations

There has been renewed interest in the use of 3,4-methylenedioxy-methamphetamine (MDMA) and serotonergic psychedelics in the treatment of multiple psychiatric disorders. Many of these compounds are known to produce prosocial effects, but how these effects relate to therapeutic efficacy and the extent to which prosocial effects are unique to a particular drug class is unknown. In this article,...

Aggressive behaviours associated with MDMA and psychedelics: a narrative review

Acta Neuropsychiatrica February 8, 2024 Negar Sayrafizadeh, Nicole Ledwos, Muhammad Ishrat Husain et al. 3 citations

Abstract Objective: Monoamine neurotransmitters play a role in aggression, especially when altered by illicit substances. However, some literature suggests that not all illicit substances may lead to aggression, notably psychedelics. This narrative review investigates the associations between serotonergic psychedelics and MDMA on aggressive behaviour. Methods: PubMed and PsycINFO were searched...

Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.

ACS Medicinal Chemistry Letters February 8, 2024 Navoda Jayakodiarachchi, Mallory A Maurer, Daniel C Schultz et al. 6 citations

Herein, we report the synthesis and characterization of a novel set of substituted indazole-ethanamines and indazole-tetrahydropyridines as potent serotonin receptor subtype 2 (5-HT2) agonists. Specifically, we examine the 5-HT2 pharmacology of the direct indazole analogs of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and related serotonergic tryptamines, and highlight the need for rigorous...

DOI: 10.1021/acsmedchemlett.3c00566 (opens in new tab) Full text (opens in new tab) Drug development Serotonin receptors Medicinal chemistry Pharmacology

Microdosing ketamine in Drosophila does not block serotonin reuptake, but causes complex behavioral changes mediated by glutamate and serotonin receptors

Journal of Neurochemistry February 7, 2024 Kelly E. Dunham, Kani H. Khaled, Leah Weizman et al.

Microdosing ketamine is a novel antidepressant for treatment‐resistant depression. Traditional antidepressants, like selective serotonin reuptake inhibitors (SSRIs), inhibit serotonin reuptake, but it is not clear if ketamine shows a similar mechanism. Here, we tested the effects of feeding ketamine and SSRIs to Drosophila melanogaster larvae, which has a similar serotonin system to mammals and...

Effect of Bulky N-Dibenzofuranylmethyl Substitution on the 5-HT2 Receptor Affinity and Efficacy of a Psychedelic Phenethylamine.

ACS Chemical Neuroscience February 7, 2024 Breno A. Soares, Thirumal Yempala, Darío Martínez-afani et al. 4 citations

The introduction of arylmethyl substituents on the amine nitrogen atom of phenethylamines and tryptamines often results in profound increases in their affinity and functional activity at 5-HT2 serotonin receptors. To probe the sensitivity of this effect to substantially larger N-substituents, ten derivatives of the well-characterized psychedelic phenethylamine 2C-B were prepared by appending...

DOI: 10.1021/acschemneuro.3c00639 (opens in new tab) Full text (opens in new tab) 5-ht2 receptor agonism 5-ht2 receptor binding Bulky n-substituents Docking poses +6

Who are you after psychedelics? A systematic review and a meta-analysis of the magnitude of long-term effects of serotonergic psychedelics on cognition/creativity, emotional processing and personality

Neuroscience & Biobehavioral Reviews February 3, 2024 Ivana Solaja, Kate Haldane, Natasha L. Mason et al. 17 citations

This systematic review and a meta-analysis synthesised the results from contemporary, randomized and non-randomized controlled studies to assess lasting (one week minimum) changes on cognition/creativity, emotional processing and personality from serotonergic psychedelics. PubMed, Embase and PsycInfo were searched in July 2022. Risk of bias was assessed using Rob 2.0 and ROBINS-I. Ten studies...

Effects of hallucinogenic drugs on the human heart

Frontiers in Pharmacology February 2, 2024 Joachim Neumann, Stefan Dhein, Uwe Kirchhefer et al. 12 citations

Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely, 5-HT 2A -serotonin receptors in the brain. However, a close study reveals that they also act on the heart, possibly increasing the force of contraction and beating rate and may lead to arrhythmias. Here, we will review...

Established sensitization of ethanol-induced locomotor activity is not reversed by psilocybin or the 5-HT2A receptor agonist TCB-2 in male DBA/2J mice.

Pharmacology, Biochemistry, and Behavior February 1, 2024 Paul J Fletcher, Zhaoxia Li, Xiao Dong Ji et al. 2 citations

Psychedelic drugs, which share in common 5-HT2A receptor agonist activity, have shown promise in treating alcohol-use disorders (AUDs). Repeated exposure to ethanol (EtOH) induces molecular and behavioural changes reflective of neuroadaptations that may contribute to addiction. Psychedelic drugs can induce neuroplasticity also, raising the possibility that their potential clinical effects in...

Do the therapeutic effects of psilocybin involve actions in the gut?

TIPS - Trends in Pharmacological Sciences February 1, 2024 Felicia Reed, Claire J. Foldi 22 citations

The psychedelic compound psilocybin has recently emerged as a therapeutic intervention for various mental health conditions. Psilocybin is a potent agonist of serotonin (5-HT) receptors (5-HTRs), which are expressed in the brain and throughout peripheral tissues, with particularly high expression in the gastrointestinal (GI) tract. However, no studies have investigated the possibility that...

Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging February 1, 2024 Friederike Holze, Nirmal Singh, Matthias E. Liechti et al. 50 citations

Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), all of which are serotonin 2A receptor agonists, are being investigated as potential treatments. This review aims to summarize the current clinical research on these 4 compounds and mescaline to guide future research. Their mechanism(s)...

Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study.

Journal of Psychopharmacology January 27, 2024 Jessica Barbut Siva, Tommaso Barba, Hannes Kettner et al. 29 citations

Background: There is growing evidence for the therapeutic effects of psychedelics. However, it is still uncertain how these drugs interact with serotonergic antidepressants (serotonin reuptake inhibitors (SRIs)). Objective: This study explores the interaction between psychedelics and SRIs in terms of therapeutic effects. The objective is to compare acute psychedelic effects and subsequent...

DOI: 10.1177/02698811231224217 (opens in new tab) Full text (opens in new tab) Psychedelics Antidepressants Mental health Drug interactions +1

Serotonin-2 Receptor Agonists Produce Anti-inflammatory Effects through Functionally Selective Mechanisms That Involve the Suppression of Disease-Induced Arginase 1 Expression

ACS Pharmacology & Translational Science January 25, 2024 Thomas W. Flanagan, Timothy P. Foster, Thomas E. Galbato et al. 18 citations

Functional selectivity in the context of serotonin 2A (5-HT 2A ) receptor agonists is often described as differences psychedelic compounds have in the activation of Gq vs β-arrestin signaling in the brain and how that may relate to inducing psychoactive and hallucinatory properties with respect to each other. However, the presence of 5-HT 2A receptors throughout the body in several cell types,...

Psilocybin biphasically modulates cortical and behavioral activity in mice

bioRxiv (Cold Spring Harbor Laboratory) January 20, 2024 Adam T. Brockett, Nikolas A. Francis 1 citation preprint

SUMMARY Psilocybin is a serotonergic psychedelic believed to have therapeutic potential for neuropsychiatric conditions. Despite well-documented prevalence of perceptual alterations, hallucinations, and synesthesia associated with psychedelic experiences, little is known about how psilocybin affects sensory cortex or alters the activity of neurons in awake animals. To investigate, we conducted...

High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin

Molecular Psychiatry January 17, 2024 Dotan Braun, Ayelet M Rosenberg, Elad Rabaniam et al. 32 citations

Abstract Serotonergic psychedelics are emerging therapeutics for psychiatric disorders, yet their underlying mechanisms of action in the brain remain largely elusive. Here, we developed a wide-field behavioral tracking system for larval zebrafish and investigated the effects of psilocybin, a psychedelic serotonin receptor agonist. Machine learning analyses of precise body kinematics identified...

Psychedelic-like Activity of Norpsilocin Analogues

ACS Chemical Neuroscience January 8, 2024 Alexander M. Sherwood, Elise K. Burkhartzmeyer, Samuel E. Williamson et al. 18 citations

Primary metabolites of mushroom tryptamines, psilocybin and baeocystin (i.e., psilocin and norpsilocin), exhibit potent agonist activity at the serotonin 2A receptor (5-HT2A) in vitro but differ in their 5-HT2A-mediated effects in vivo. In particular, psilocin produces centrally mediated psychedelic effects in vivo, whereas norpsilocin, differing only by the loss of an N-methyl group, is devoid...

DOI: 10.1021/acschemneuro.3c00610 (opens in new tab) Serotonin In vivo Pharmacology Stereochemistry +4

5-HT2A Receptor Knockout Mice Show Sex-Dependent Differences following Acute Noribogaine Administration.

International Journal of Molecular Sciences January 5, 2024 Sofía Villalba, Bruno González, Stephanie Junge et al. 9 citations

Noribogaine (noribo) is the primary metabolite from ibogaine, an atypical psychedelic alkaloid isolated from the root bark of the African shrub Tabernanthe iboga. The main objective of this study was to test the hypothesis that molecular, electrophysiological, and behavioral responses of noribo are mediated by the 5-HT2A receptor (5-HT2AR) in mice. In that regard, we used male and female,...

Síndrome serotoninérgico inducido por ayahuasca: a propósito de un caso

Revista chilena de neuro-psiquiatría 2024 M. Laura Ortega, D. Laura Herrera, U. Patricia Caro et al. 1 citation

RESUMEN El síndrome serotoninérgico es un conjunto de signos y síntomas generados por hiperactividad serotoninérgica, caracterizado principalmente por alteración del sistema nervioso central. La medicina tradicional, históricamente utiliza herbales con fines curativos y religiosos que podrían tener efectos sobre el sistema serotoninérgico, receptores de dopamina, glutamato y noradrenalina, en...

A role for the serotonin 2A receptor in the expansion and functioning of human transmodal cortex.

Brain 2024 Andrea I. Luppi, Manesh Girn, Fernando E. Rosas et al. 25 citations

Integrating independent but converging lines of research on brain function and neurodevelopment across scales, this article proposes that serotonin 2A receptor (5-HT2AR) signalling is an evolutionary and developmental driver and potent modulator of the macroscale functional organization of the human cerebral cortex. A wealth of evidence indicates that the anatomical and functional organization...

DOI: 10.1093/brain/awad311 (opens in new tab) Evolutionary expansion Uniquely human-expanded areas Transmodal cortex Sophisticated functioning +7

Mechanisms of SSRI Therapy and Discontinuation.

Current Topics in Behavioral Neurosciences 2024 Trevor Sharp, Helen M Collins 40 citations

SSRIs are one of the most widely used drug therapies in primary care and psychiatry, and central to the management of the most common mental health problems in today's society. Despite this, SSRIs suffer from a slow onset of therapeutic effect and relatively poor efficacy as well as adverse effects, with recent concerns being focused on a disabling SSRI discontinuation syndrome. The mechanism...